The 31 references in paper N. Pogudina L., E. Kosolapov G., F. Kochenkov S., A. Karaulov V., N. Bondarenko L., D. Blinov V., Н. Погудина Л., Е. Косолапов Г., Ф. Коченков С., А. Караулов В., Н. Бондаренко Л., Д. Блинов В. (2017) “Сравнительный анализ минимизации затрат и влияния на бюджет фиксированных комбинаций ингаляционных глюкокортикостероидов и длительно действующих бета-агонистов для лечения астмы // COMPARATIVE COST-MINIMIZATION AND BUDGET-IMPACT ANALYSIS OF FIXED-DOSE INHALED CORTICOSTEROID / LONG-ACTING BETAAGONIST COMBINATIONS IN THE TREATMENT OF ASTHMA” / spz:neicon:pharmacoeconomics:y:2017:i:2:p:12-21

1
Global Strategy for Asthma Management and Prevention. 2017. URL: www.ginasthma.org. Accessed: 12.04.2017.
(check this in PDF content)
2
Bronchial asthma. Clinical guidelines. MOO Russian respiratory society, IMO Paediatric respiratory society [Bronkhial’naya astma. Klinicheskie rekomendatsii. MOO Rossiiskoe respiratornoe obshchestvo, MMO Pediatricheskoe respiratornoe obshchestvo (in Russian)]. 2016; 76 s.
(check this in PDF content)
3
Chuchalin A. G. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. International Journal of Chronic Obstructive Pulmonary Disease. 2014; 9: 963-974.
(check this in PDF content)
4
Zaitsev A. A. Bronkhial’naya astma u vzroslykh: klyuchevye voprosy diagnostiki i farmakoterapii. RMZh. 2015; 18: 10961100.
(check this in PDF content)
5
The Federal target program “Bronchial asthma” (2011-2015) [Federal’naya tselevaya programma «Bronkhial’naya astma» (20112015 gody) (in Russian)]. Moscow. 2009.
(check this in PDF content)
6
Revich B. A., Khar’kova T. L. Chem boleyut i ot chego gibnut rossiyane trudosposobnogo vozrasta. Demoskop Weekly. 2016; 691692. URL: http://demoscope.ru/weekly/2016/0691/tema01.php. Accessed: 16.02.2017.
(check this in PDF content)
7
Yagudina R. I., Kulikov A. Yu., Ogorodova L. M., Demko I. V., Tolkushin A. G., Kobyakova O. S., Chuchalin A. G. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2010; 3 (1): 40-46.
(check this in PDF content)
8
Accordini S., Bugiani M., Arossa W. et al. Poor control increases the economic cost of asthma. A multicentre population-based study. Int Arch Allergy Immunol. 2006; 141 (2): 189-198.
(check this in PDF content)
9
Nazarova E. V., Latysheva E. A. RAZh. 2015; 5: 82-89.
(check this in PDF content)
10
Nenasheva N. M. Prakticheskaya Pul’monologiya. 2016; 3: 3-10.
(check this in PDF content)
11
Relvar Of Ellipta. Instruction for medical use. State registry of Medicines [Relvar Ellipta. Instruktsiya po meditsinskomu primeneniyu. Gosudarstvennyi reestr Lekarstvennykh Sredstv (in Russian)]. URL: www.grls.rosminzdrav.ru. Accessed: 26.12.2016.
(check this in PDF content)
12
Svedsater H., Stynes G., Wex J. et al. Once-daily fluticasone furoate/vilanterol versus twice daily combination therapies in asthmamixed treatment comparisons of clinical efficacy. Asthma Res Pract. 2016; 8 (2): 4. DOI: 10.1186/s40733-015-0016-0.
(check this in PDF content)
13
Hozawa S., Terada M., Haruta Y., Hozawa M. Comparison of early effects of budesonide/formoterol maintenance and reliever therapy with fluticasone furoate/vilanterol for asthma patients requiring step-up from inhaled corticosteroid monotherapy. Pulm Pharmacol Ther. 2016; 37: 15-23.
(check this in PDF content)
14
National Asthma Handbook. Version 1.1. National Asthma Council Australia, Melbourne – 2015.
(check this in PDF content)
15
Pavord I. D., Jeffery P. K., Qiu Y. et al. Airway inflammation in patients with asthma with high-fixed or low-fixed plus as-needed budesonide/formoterol. J Allergy Clin Immunol. 2009; 123 (5): 10831089, 1089. e7.
(check this in PDF content)
16
Scicchitano R., Aalbers R., Ukena D. et al. Efficacy and safety of budesonide/ formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin. 2004; 20: 1403-1418.
(check this in PDF content)
17
Rabe K. F., Atienza T., Magyar P., Larsson P., Jorup C., Lalloo U. G. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet. 2006; 368: 744.
(check this in PDF content)
18
Aubier M., Buhl R., Ekstrom T. et al. Comparison of two twicedaily doses of budesonide/formoterol maintenance and reliever therapy. Eur. Respir. J. 2010: 36: 524-530.
(check this in PDF content)
19
Demoly P., Louis R., Soes-Petersen U. et al. Budesonide/ formoterol maintenance and reliever therapy versus conventional best practice. Respir. Med. 2009; 103: 1623-1632.
(check this in PDF content)
20
Vogelmeier C., D’Urzo A., Pauwels R. et al. Budesonide/ formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur. Respir. J. 2005; 26: 819-828.
(check this in PDF content)
21
Stallberg B., Naya I., Ekelund J. et al. Follow-up programme for patients using Symbicort® Turbuhaler® maintenance and reliever therapy in real-world clinical practice. Prim. Care Respir. J. 2013; 22. A11.
(check this in PDF content)
22
Ställberg B., Naya I., Ekelund J., Eckerwall G. Real-life use of budesonide/formoterol in clinical practice: a 12-month followup assessment in a multi-national study of asthma patients established on single-inhaler maintenance and reliever therapy. International J of Clinical Pharmacology and Therapeutics. 2015; 53 (6): 447-455.
(check this in PDF content)
23
Patel M., Pichler P., Pritchard A. at al. Efficacy and safety of maintenance and reliever combination budesonide–formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Resp Med. 2013; 1 (1): 32-42.
(check this in PDF content)
24
O’Byrne P. M., Bisgaard H., Godard P. P. et al. Budesonide/ formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005; 171: 129-36.
(check this in PDF content)
25
Fassakhov R. S. Budesonid/formoterol v rezhime SMART v terapii bronkhial’noi astmy: ot vliyaniya na vospalenie do terapii fenotipov. RMZh. 2016; 16: 1059-1064.
(check this in PDF content)
26
Slack R. J., Barrett V. J., Morrison V. S. et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2adrenoceptor agonist with 24-hour duration of action. J. Pharmacol. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2017; Том 10, No 2 www.pharmacoeconomics.ru Сведения об авторах: Погудина Наталья Леонидовна – к. э.н., ООО «НИК «Разумный выбор». Адрес: Открытое шоссе, д 23, корп. 6, Москва, Россия, 107143. E-mail: Pogoudina@ya.ru. Косолапов Евгений Геннадиевич – ООО «НИК «Разумный выбор». Адрес: Открытое шоссе, д 23, корп. 6, Москва, Россия, 107143. E-mail: kj78soulpower@yandex.ru. Коченков Филипп Сергеевич – к. ф.н., ООО «НИК «Разумный выбор». Адрес: Открытое шоссе, д 23, корп. 6, Москва, Россия, 107143. E-mail: Kochenkov_filipp@hotm
(check this in PDF content)
27
Valotis A., Högger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respiratory Research. 2007; 8: 54-62.
(check this in PDF content)
28
European Medicines Agency. Summary of product characteristics: Relvar Ellipta inhalation powder. 2013. URL: http://www.ema.europa.eu/ docs/en_GB/document_library/EPAR_-_Product_Information/ human/002673/WC500157633.pdf. Accessed: 22.12.2016.
(check this in PDF content)
29
Romanovskikh A. G., Belotserkovskaya Yu. G., Styrt E. A. Klin. med. 2015; 93 (12): 38-43.
(check this in PDF content)
30
Hren R., Stynes G. Cost-Minimization and Budget-Impact Analysis of Fixed-Dose Combination Inhalers in Treatment of COPD in Slovenia. Value Health. 2014; 17 (7): A592. DOI: 10.1016/j. jval.2014.08.2032.
(check this in PDF content)
31
Hren R., Trkman M., Stynes G. Cost-Minimization and BudgetImpact Analysis of Fixed-Dose ICS/LABA Combination Inhalers in the Treatment of Asthma in Slovenia. Value Health. 2014; 17 (7): A592. DOI: 10.1016/j.jval.2014.08.2031.
(check this in PDF content)